May 29, 2020 / 1:07 PM / a month ago

BRIEF-Beigene Presents Phase 3 Data On Tislelizumab Combined With Chemotherapy For The Treatment Of Patients With Advanced Squamous Non-Small Cell Lung Cancer

May 29 (Reuters) - Beigene Ltd:

* BEIGENE PRESENTS PHASE 3 DATA ON TISLELIZUMAB COMBINED WITH CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL SCIENTIFIC PROGRAM

* BEIGENE LTD - PHASE 3 RESULTS COMPARING TISLELIZUMAB PLUS CHEMOTHERAPY TO CHEMOTHERAPY ALONE MET ITS PRIMARY ENDPOINT

* BEIGENE LTD - OBJECTIVE RESPONSE RATES (ORR) WERE MEANINGFULLY HIGHER FOR PATIENTS RECEIVING TISLELIZUMAB

* BEIGENE LTD - TREATMENT WITH TISLELIZUMAB AND CHEMOTHERAPY WAS GENERALLY WELL-TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below